相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Mathias Vormehr et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme
Jun-Qi Li et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
M. E. Rodriguez-Ruiz et al.
ANNALS OF ONCOLOGY (2018)
Methods for improving the immunogenicity and efficacy of cancer vaccines
Lorenzo Pilla et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Dendritic Cell-Based Cancer Vaccines
Patricia M. Santos et al.
JOURNAL OF IMMUNOLOGY (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Janos L. Tanyi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
The Clinicopathological and Prognostic Significance of IDO1 Expression in Human Solid Tumors: Evidence from a Systematic Review and Meta-Analysis
Cheng-Peng Yu et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment
Mansi Saxena et al.
TRENDS IN CANCER (2018)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Thomas C. Wirth et al.
FRONTIERS IN IMMUNOLOGY (2017)
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2017)
Lessons learned from cancer vaccine trials and target antigen choice
Lisa H. Butterfield
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
Sofie Wilgenhof et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane A. Mitchell et al.
NATURE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients
Michael A. Morse et al.
CLINICAL CANCER RESEARCH (2011)
Induction of CD8+ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Hideho Okada et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
Soyoung Baek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation
Leisha A. Emens et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
Sylvia Adams et al.
JOURNAL OF IMMUNOLOGY (2008)
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity
RM Prins et al.
JOURNAL OF IMMUNOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation
S Nair et al.
JOURNAL OF IMMUNOLOGY (2003)
分享论文
